Rezolute (RZLT) said Tuesday it has received the US Food and Drug Administration's
Breakthrough Therapy designation for its ersodetug monoclonal antibody to treat hypoglycemia due to congenital hyperinsulinism.
The regulator's decision was based on the company's phase 2b trial of ersodetug in patients with congenital hyperinsulinism, which "safely" showed "significant improvements" in hypoglycemia by at least 75%, with no clinically significant hyperglycemia, Rezolute added.
The company said it intends to start its phase 3 trial for tumor hyperinsulinism this year.
Shares of the company rose 3.6% in recent Tuesday trading.
Price: 5.40, Change: +0.19, Percent Change: +3.55
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.